GLMD News and Press, Galmed Pharmaceuticals Ltd.

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers PR Newswire Recently, Galmed announced breakthrough medicinal chemistry work converting Aramchol into a brain-penetr...

2026-04-09 10:00:53 ET Denver, Colorado - A wave of innovation across AI robotics, biotechnology, advanced materials, and clean energy is reshaping the small-cap landscape. At the center of the AI conversation is Onconetix (NASDAQ:ONCO) , which is leveraging its pending acquisition ...

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol PR Newswire 98% of drugs do not reach the brain, as the blood–brain barrier (BBB) separates peripheral blood circulation from the central nervous system (CNS)...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 PR Newswire TEL AVIV, Israel , March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical compan...

2026-01-30 16:29:40 ET More on Galmed Seeking Alpha’s Quant Rating on Galmed Historical earnings data for Galmed Financial information for Galmed Read the full article on Seeking Alpha For further details see: Galmed Pharmaceuticals receive...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel , Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiom...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR Newswire Late Breaking Abstract titled " Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study ...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH PR Newswire The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (U...

Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel , Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal onco...

2025-11-26 08:36:57 ET More on Galmed Seeking Alpha’s Quant Rating on Galmed Historical earnings data for Galmed Financial information for Galmed Read the full article on Seeking Alpha For further details see: Galmed GAAP EPS of -$0.33 beat...